Disease Vs
Disease Vs
Podcast Description
Disease Vs is all about diving into the biggest battles in modern science — from cancer to antibiotic resistance — and uncover how breakthroughs in biomedical research are reshaping how we treat diseases and deal with global heath challenges!
Podcast Insights
Content Themes
The podcast covers a wide array of topics related to disease management and scientific advancements, with specific themes including cancer treatments, antibiotic resistance, female infertility, and multiple sclerosis therapies. Examples of episodes include examinations of targeted vs. non-targeted cancer therapies, the implications of age-related female infertility interventions, and the impact of monoclonal antibodies on multiple sclerosis treatment.
Disease Vs is all about diving into the biggest battles in modern science — from cancer to antibiotic resistance — and uncover how breakthroughs in biomedical research are reshaping how we treat diseases and deal with global heath challenges!
Ryan, Isabelle and Long delve into the ever-changing world of cancer treatments. They discuss both targeted and non-targeted treatment strategies and what the future of cancer treatment may look like!
References
1. Voorhees P. Case Presentation: A 63-Year-Old Patient with Relapsed-Refractory (R/R) Multiple Myeloma [Internet]. Targeted Oncology. 2023. Available from: https://www.targetedonc.com/view/case-presentation-a-63-year-old-patient-with-relapsed-refractory-r-r-multiple-myeloma
2. Understanding What Cancer Is: Ancient Times to Present . Cancer.org. 2018. Available from: https://www.cancer.org/cancer/understanding-cancer/history-of-cancer/what-is-cancer.html#:~:text=Human%20beings%20and%20other%20animals,%E2%80%9CThere%20is%20no%20treatment.%E2%80%9D
3. Cancer in Australia statistics. Cancer Australia. 2022. Available from: https://www.canceraustralia.gov.au/research-data/data-and-statistics/cancer-australia-statistics
4. Cancer information and support [Internet]. Cancer.org.au. 2021. Available from: https://www.cancer.org.au/
5. What is Chemotherapy? | Chemo Treatment for Cancer [Internet]. Cancer.org. 2025.
6. Radiation therapy – Mayo Clinic [Internet]. Mayoclinic.org.; 2025.
7. Radiation Therapy for Cancer [Internet]. Cancer.gov. 2019.
8. Yasemin Ceyhan, Marie N, Alvarez JV. Immune cells in residual disease and recurrence. Trends in cancer [Internet]. 2023 May 5;9(7):554–65.
9. Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology & Oncology. 2019 Dec 1;12(1).
10. Gregory A. “Amazing” trial shows drug combination stops lung cancer advancing for longer [Internet]. The Guardian. The Guardian; 2024.
11. Xiang Y, Liu X, Wang Y, Zheng D, Meng Q, Jiang L, et al. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges. Frontiers in Immunology [Internet]. 2024 Apr 9;15.
12. Personalized Medicine [Internet]. Genome.gov. 2025.
13. Rivera-Soto R, Henley B, Pulgar MA, Lehman SL, Gupta H, Perez-Vale KZ, et al. Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression. npj Precision Oncology [Internet]. 2024 Sep 6;8(1).
14. Immune Checkpoint Inhibitors [Internet]. Cancer.gov. 2022.
15. Liu L, Krishnan A. Talquetamab in multiple myeloma. Haematologica [Internet]. 2023 Oct 19 ;109(3):718–24.
16. Ma Y, Gan J, Bai Y, Cao D, Jiao Y. Minimal residual disease in solid tumors: an overview. Frontiers of Medicine [Internet]. 2023 Aug 1;17(4):649–74.
17. B Martínez-Castedo, Camblor DG, J Martín-Arana, Carbonell-Asins JA, B García-Micó, Gambardella V, et al. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Annals of Oncology [Internet]. 2024
18. Peker YS, Can MF, Ismail Hakki Ozerhan, Gokhan Yagci, Nazif Zeybek, Kutan Kavakli, et al. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. Case Reports in Surgery [Internet]. 2018 Jan 1 ;2018:1–6.
19. Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology & Oncology [Internet]. 2019 Dec 1;12(1).
20. Ahn M, Tsai C, Shepherd FA, Lyudmila Bazhenova, Sequist LV, Hida T, et al. Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies. Cancer [Internet]. 2018 Dec 4;125(6):892–901.
21. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology [Internet]. 2017 Mar 2;14(9):531–48.
22. DePolo J. Triple-Negative Breast Cancer (TNBC) [Internet]. Breastcancer.org. 2022 .
23. Beasley D. Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type [Internet]. Reuters. 2025.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.